Overview

• US eyecare technology firm's Q1 revenue rose 13%, beating analyst expectations

• Company raised full-year 2026 revenue guidance

• Q1 net loss narrowed from prior year, gross margin held steady at 86%

Outlook

• Sight Sciences raises 2026 revenue guidance to $83 mln-$89 mln from $82 mln-$88 mln

• Company expects 2026 Interventional Glaucoma revenue of $77 mln-$81 mln, up 2%-7%

• Sight Sciences reaffirms 2026 adjusted operating expenses guidance of $93 mln-$96 mln

Result Drivers

• GLAUCOMA SEGMENT - Revenue growth in Interventional Glaucoma driven by more ordering accounts and higher average selling prices, partially offset by lower utilization per account

• DRY EYE SEGMENT - Interventional Dry Eye revenue surged due to higher average selling prices, increased utilization, and more ordering accounts

• COST MANAGEMENT - Cash usage improved 40% year-over-year, reflecting disciplined operating expense and cash management

Company press release: ID:nGNX3j7FGq

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Sight Sciences Inc is $8.50, about 96.3% above its May 5 closing price of $4.33

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.